CHAMPS is the acronym for the Controlled High-Risk Subject Multiple Sclerosis Prevention Study.

Main inclusion criterion: An acute demyelinating event with MRI signal abnormalities.

Pts randomized to Avonex vs placebo.

Avonex is interferon β-1a.

In addition to Avonex, all patients received the Optic Neuritis Treatment Trial IV steroid dosing.

Result: Avonex treatment produced a 44% reduction in the onset of CDMS at 3 years.
CHAMPS is the acronym for the Controlled High-Risk Subject Avonex MS Prevention Study.
CHAMPS is the acronym for the Controlled High-Risk Subject Avonex MS Prevention Study.

Main inclusion criterion: An acute event with MRI signal abnormalities.

Pts randomized to Avonex vs placebo.

Avonex is interferon $\beta$-1a.

In addition to Avonex, all patients received the Optic Neuritis Treatment Trial IV steroid dosing.

Result: Avonex treatment produced a 44% reduction in the onset of CDMS at 3 years.
CHAMPS is the acronym for the **Controlled High-Risk Subject Avonex MS Prevention** Study.

Main inclusion criterion: An acute **demyelinating** event with MRI **signal abnormalities**.
CHAMPS is the acronym for the Controlled High-Risk Subject Avonex MS Prevention Study. Main inclusion criterion: An acute demyelinating event with MRI signal abnormalities. Pts randomized to Avonex vs placebo. Result: Avonex treatment produced a 44% reduction in the onset of CDMS at 3 years.
CHAMPS is the acronym for the Controlled High-Risk Subject Avonex MS Prevention Study.

Main inclusion criterion: An acute demyelinating event with MRI signal abnormalities.

Pts randomized to Avonex vs placebo.

Avonex is the generic name.
CHAMPS is the acronym for the Controlled High-Risk Subject Avonex MS Prevention Study.

Main inclusion criterion: An acute demyelinating event with MRI signal abnormalities.

Pts randomized to Avonex vs placebo.

Avonex is interferon β-1a.
CHAMPS is the acronym for the Controlled High-Risk Subject Avonex MS Prevention Study.

Main inclusion criterion: An acute demyelinating event with MRI signal abnormalities.

Pts randomized to Avonex vs placebo.

Avonex is interferon β-1a.

In addition to Avonex, all patients received the IV steroid dosing.
The CHAMPS

- CHAMPS is the acronym for the Controlled High-Risk Subject Avonex MS Prevention Study
- Main inclusion criterion: An acute demyelinating event with MRI signal abnormalities
- Pts randomized to Avonex vs placebo
- Avonex is interferon β-1a
- In addition to Avonex, all patients received the Optic Neuritis Treatment Trial IV steroid dosing
CHAMPS is the acronym for the Controlled High-Risk Subject Avonex MS Prevention Study.

Main inclusion criterion: An acute demyelinating event with MRI signal abnormalities.

Pts randomized to Avonex vs placebo.

Avonex is interferon β-1a.

In addition to Avonex, all patients received the Optic Neuritis Treatment Trial IV steroid dosing.

Result: Avonex treatment produced a 44% reduction in the onset of CDMS at 3 years.
CHAMPS is the acronym for the Controlled High-Risk Subject Avonex MS Prevention Study.

Main inclusion criterion: An acute demyelinating event with MRI signal abnormalities.

Pts randomized to Avonex vs placebo.

Avonex is interferon β-1a.

In addition to Avonex, all patients received the Optic Neuritis Treatment Trial IV steroid dosing.

Result: Avonex treatment produced a 44% reduction in the onset of CDMS at 3 years.
CHAMPS is the acronym for the 
Controlled High-Risk Subject Avonex MS Prevention Study

Main inclusion criterion: An acute demyelinating event with MRI signal abnormalities

Pts randomized to Avonex vs placebo

Avonex is interferon β-1a

In addition to Avonex, all patients received the Optic Neuritis Treatment Trial IV steroid dosing

Result: Avonex treatment produced a 44% reduction in the onset of CDMS at 3 years

What does CDMS stand for?
CHAMPS is the acronym for the Controlled High-Risk Subject Avonex MS Prevention Study.

Main inclusion criterion: An acute demyelinating event with MRI signal abnormalities.

Pts randomized to Avonex vs placebo.

Avonex is interferon β-1a.

In addition to Avonex, all patients received the Optic Neuritis Treatment Trial IV steroid dosing.

Result: Avonex treatment produced a 44% reduction in the onset of CDMS at 3 years.

CHAMPS is the acronym for the Controlled High-Risk Subject Avonex MS Prevention Study.

**Main inclusion criterion:** An acute demyelinating event with MRI signal abnormalities.

Pts randomized to Avonex vs placebo.

Avonex is interferon β-1a.

In addition to Avonex, all patients received the Optic Neuritis Treatment Trial IV steroid dosing.

Result: Avonex treatment produced a 44% reduction in the onset of CDMS at 3 years.
CHAMPS is the acronym for the Controlled High-Risk Subject Avonex MS Prevention Study.

- Main inclusion criterion: An acute demyelinating event with MRI signal abnormalities.
- Pts randomized to Avonex vs placebo.
- Avonex is interferon β-1a.
- In addition to Avonex, all patients received the Optic Neuritis Treatment Trial IV steroid dosing.
- Result: Avonex treatment produced a 44% reduction in the onset of CDMS at 3 years.
CHAMPS is the acronym for the Controlled High-Risk Subject MS Prevention Study.

Main inclusion criterion: An acute demyelinating event with MRI signal abnormalities.

Pts randomized to Avonex vs placebo.

Avonex is interferon $\beta$-1a.

In addition to Avonex, all patients received the Optic Neuritis Treatment Trial IV steroid dosing.

Result: Avonex treatment produced a 44% reduction in the onset of CDMS at 3 years.

Name two other immunomodulating agents proven effective in delaying the onset of CDMS:

--

--

Avonex, Betaseron, and Copaxone are called the 'ABC meds for MS.'
CHAMPS is the acronym for the Controlled High-Risk Subject MS Prevention Study.

Main inclusion criterion: An acute demyelinating event with MRI signal abnormalities.

Pts randomized to Avonex vs placebo.

Avonex is interferon β-1a.

In addition to Avonex, all patients received the Optic Neuritis Treatment Trial IV steroid dosing.

Result: Avonex treatment produced a 44% reduction in the onset of CDMS at 3 years.

Name two other immunomodulating agents proven effective in delaying the onset of CDMS:
--IFNβ-1b
--Glatiramer acetate

Avonex is interferon β-1a.

In addition to Avonex, all patients received the Optic Neuritis Treatment Trial IV steroid dosing.

Result: Avonex treatment produced a 44% reduction in the onset of CDMS at 3 years.

The 'ABC meds' for MS.
The CHAMPS

Name two other immunomodulating agents proven effective in delaying the onset of CDMS:
--IFNβ-1b
--Glatiramer acetate

What are their brand names?
--IFNβ-1b:
--Glatiramer acetate:

● Avonex is interferon β-1a
● In addition to Avonex, all patients received the Optic Neuritis Treatment Trial IV steroid dosing
● Result: Avonex treatment produced a 44% reduction in the onset of CDMS at 3 years
CHAMPS is the acronym for the Controlled High-Risk Subject Multiple Sclerosis Prevention Study.

Main inclusion criterion: An acute demyelinating event with MRI signal abnormalities.

Pts randomized to Avonex vs placebo.

Avonex is interferon β-1a.

In addition to Avonex, all patients received the Optic Neuritis Treatment Trial IV steroid dosing.

Result: Avonex treatment produced a 44% reduction in the onset of CDMS at 3 years.

Name two other immunomodulating agents proven effective in delaying the onset of CDMS:
--IFNβ-1b
--Glatiramer acetate

What are their brand names?
--IFNβ-1b: Betaseron
--Glatiramer acetate: Copaxone

Avonex is interferon β-1a.

In addition to Avonex, all patients received the Optic Neuritis Treatment Trial IV steroid dosing.

Result: Avonex treatment produced a 44% reduction in the onset of CDMS at 3 years.
CHAMPS is the acronym for the Controlled High-Risk Subject MS Prevention Study.

- Main inclusion criterion: An acute demyelinating event with MRI signal abnormalities
- Pts randomized to Avonex vs placebo
- Avonex is interferon β-1a
- In addition to Avonex, all patients received the Optic Neuritis Treatment Trial IV steroid dosing
- Result: Avonex treatment produced a 44% reduction in the onset of CDMS at 3 years

Name two other immunomodulating agents proven effective in delaying the onset of CDMS:
--IFNβ-1b
--Glatiramer acetate

What are their brand names?
--IFNβ-1b: Betaseron
--Glatiramer acetate: Copaxone

Together, what are Avonex, Betaseron and Copaxone called? The 'ABC meds' for MS

- **Avonex** is **interferon β-1a**
- In addition to Avonex, all patients received the **Optic Neuritis Treatment Trial IV steroid dosing**
- Result: Avonex treatment produced a **44%** reduction in the onset of CDMS at 3 years
The CHAMPS

Name two other immunomodulating agents proven effective in delaying the onset of CDMS:
--IFNβ-1b
--Glatiramer acetate

What are their brand names?
--IFNβ-1b: Betaseron
--Glatiramer acetate: Copaxone

Together, what are Avonex, Betaseron and Copaxone called?
The ‘ABC meds’ for MS

● **Avonex is interferon β-1a**

● In addition to Avonex, all patients received the Optic Neuritis Treatment Trial IV steroid dosing

● Result: Avonex treatment produced a 44% reduction in the onset of CDMS at 3 years